What is LDN’s Impact on Toll-like Receptors?

This presentation explores the role of Toll-Like Receptors (TLRs) in immune responses and their connection to diseases like cancer. It highlights previous findings on naltrexone's inhibition of TLR4 and presents new research investigating naltrexone's potential to inhibit various TLRs in human immune cells. The study also touches upon naltrexone's effectiveness in long COVID and its possible impact on TLR9.

Professor Angus Dalgleish: Talllike receptors TLR they play a fundamental role in the immune response by providing initial danger signal that triggers downstream immune activity. There are many different members and they're expressed by different immune cells and indeed different cells as is the case with neural cells. Inappropriate TLR activity is associated with inflammatory diseases, cancer and autoimmunity. And now trexone inhibiting TLR in a model cell system and rat neural cells by Hutcherson atal is completely different from our studies but also I believe very important a very important difference. We imported we therefore performed a study to see whether nrexone could inhibit different TLR9 in human immune cells. With regards to the TLR4, I would just like to point out why I think this is important. as we found that lowd dose nrexone is very effective in patients with long COVID where IL6 is a major marker of acute activity as well as a very good marker for the progression into long COVID full stop. Many of these patients report great benefit over several weeks with lowd dose nrexone and we think this is almost certainly related to the reduction in interlucan 6. However, I have been really impressed by the number of patients who report a much quicker improvement in brain fog often within 48 hours. And this suggests to me this might be associated with the ability to hit TLR9 in gal cells. It is an interesting speculation and has yet to be proven. Now my main interest is cancer.